22 / 34
Page 50
Notes:
allied
academies
Ophthalmol Case Rep 2017 Volume 1 Issue 1
August 21-23, 2017 | Toronto, Canada
EYE AND VISION
3
rd
International Conference on
Purpose:
To compare the anti-inflammatory efficacy of
nepafenac 0.3% eye drops for prophylaxis of macular edema
(ME) after small-incision cataract extraction.
Design:
Randomized prospective intraindividual comparative
study.
Methods:
Both eyes of patients with bilateral age-related
cataract were evaluated. Each patient was assigned
randomly to receive a nepafenac 0.3% drops (Nevanac Uno,
Alcon) in one eye (Nepafenac Group: Case) and a topical
artificial tear substitute in the fellow eye (Placebo Group:
Control). The primary outcome measure was the change
in spectral-domain optical coherence tomography (SD-
OCT) mean central subfield thickness (CST, μm) and total
macular volume (TMV, mm3) at 1 week, 5 and 12 weeks
postoperatively compared between groups. The percentage
of patients in both groups who demonstrated macular
edema (≥30% increase from preoperative baseline in CST),
and the best-corrected distance visual acuity (CDVA) within
5 and 12 weeks after cataract surgery were also compared
between groups.
Results:
Two hundred and six eyes of 103 patients were
included in this study. In all retinal thickness measurements,
a significant increase in both groups was detected starting
from the postoperative first week until 12 weeks. At 5
weeks, there was a statistically significant difference in
CST and TMV between the nepafenac and control group
(P=0.024 and P=0.015, respectively). At the 5th post-
operative week, none of eyes in the nepafenac group and
4 (3.88%) eyes of the control group showed macula edema,
Nonsteroidal antiinflammatory!2 highlighting a trend
toward greater incidence in the control group. The between-
group differences in visual outcomes were not statistically
significant.
Conclusion:
Used prophylactically after uneventful cataract
surgery, nepafenac 0.3% was efficacious in reducing macular
thickness compared to placebo after 5weeks postoperatively,
without difference in final visual acuity.
Keywords:
Macular edema; cystoid macular edema;
nonsteroidal anti-inflammatory agent; optical coherence
tomography; phacoemulsification; nepafenac.
Speaker Biography
Clézio Soares Morato is a Medical Specialist in Ophthalmology. I was graduated from
Ciências Médicas de Minas Gerais University – FCMMG (in Belo Horizonte, Minas
Gerais, Brazil) and his Residency at the Base Hospital of the Federal District - Brasília
– DF (Brazil).
Presently, I ammember of the Brazilian Council of Ophthalmology. I am currently doing
a Fellowship in Corneal and external disease section of the Ophthalmology Reference
Centre (CEROF) in Goiania, Goiás, Brazil
e:
clezio_soares@yahoo.com.brIntraindividual comparison of nepafenac 0.3% for the prevention of macular edema after
phacoemulsification: Prospective placebo-controlled randomized study
Clézio Soares Morato
University Goiania Goias, Brazil